Courtney Rubin
Dermatology · Boston, MANPI 1407218670
Payments from drug & device makers
Across 163 payments — averaging $28.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Sanofi$862
- Teladoc Health, Inc.$500
- Novartis$330
- Revance Therapeutics, Inc.$329
- Regeneron Healthcare Solutions, Inc.$311
- plus $883 from 14 others
What the payments were for
- Consulting fees$2505%
- Speaking & faculty fees$2505%
- Food & beverage$4,21289%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 63 | $1,498 |
| Sanofi | 22 | $862 |
| Teladoc Health, Inc. | 2 | $500 |
| Novartis | 12 | $330 |
| Revance Therapeutics, Inc. | 8 | $329 |
| Regeneron Healthcare Solutions, Inc. | 10 | $311 |
| Incyte Corporation | 16 | $260 |
| UCB, Inc. | 6 | $155 |
| LEO Pharma Inc. | 5 | $105 |
| Lilly USA, LLC | 3 | $65 |
| Johnson & Johnson | 3 | $55 |
| Almirall LLC | 2 | $47 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 2 | $39 |
| Amgen | 2 | $35 |
| Biofrontera Inc. | 2 | $33 |
| Verrica Pharmaceuticals Inc. | 1 | $20 |
| Pfizer | 1 | $19 |
| Arcutis Biotherapeutics, Inc. | 1 | $19 |
| Galderma Laboratories, L.p. | 1 | $17 |
| Boehringer Ingelheim | 1 | $14 |
How this compares
$4,712 in reported general payments places this provider in the 70th percentile of 552 dermatology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 11 | $37,702 |
| Clobetasol Propionate | 28 | $1,637 |
| Ketoconazole | 39 | $1,100 |
| Fluorouracil | 18 | $952 |
| Clindamycin Phosphate | 12 | $687 |
| Metronidazole | 11 | $536 |
| Fluocinolone Acetonide | 13 | $500 |
| Nystatin | 12 | $368 |
| Triamcinolone Acetonide | 45 | $364 |
| Mupirocin | 11 | $121 |
| Hydrocortisone | 11 | $43 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Boston
- Alexandra KimballBoston$3.7M
- Gideon SmithBoston$2.6M
- Tarannum JaleelBoston$1.3M
- Maria Beatrice AloraBoston$1.3M
- Martina PorterBoston$1.1M
- Arash MostaghimiBoston$1M
- Emmy GraberBoston$882K
- Ruth Ann VleugelsBoston$786K
- Maryanne SennaBoston$783K
- Gabriela CobosBoston$558K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.